Condition: Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment · Sponsor: Unity Health Toronto
Intravitreal topotecan has anti-inflammatory, anti-proliferative and anti-fibrotic activity that we hypothesize may exhibit high efficacy for the treatment of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment (RRD). A high efficacy for intravitreal topotecan has been exhibited in cell cultures of PVR. At the same time, intravitreal topotecan has been routinely used in the treatment of vitreous seeds from retinoblastoma. At doses of 5-30 micrograms per injection, no adverse events have been reported with the use of intravitreal topotecan. Therefore, the current prospective matched phase II trial aims to investigate the efficacy and safety of intravitreal topotecan for severe PVR in patients with RRD.
This description comes directly from the study's public registry record.
Rajeev Muni, MD · 416-867-7411 · rajeev.muni@utoronto.ca
Marko Popovic, MD · 416-867-7411 · marko.popovic@mail.utoronto.ca
Always discuss trial participation with your own doctor first.
| Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada | Recruiting |
| St. Michael's Hospital | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05523869